268 Sterol carrier protein-like
Ligands and drugs
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
ClassyFire chemical superclasses of the ligands bound by this X-group's proteins, from DrugDomain annotations.
The raw number of superclasses rises with the number of proteins sampled; the per-20 value compares X-groups at equal depth.
| Superclass | Proteins | Expected | 0.25×observed / expected4× | Ratio | Significance |
|---|---|---|---|---|---|
| Homogeneous metal compounds | 7 | 10.7 | 0.66× | q = 0.19 | |
| Nucleosides, nucleotides, and analogues | 0 | 6.0 | 0 | q = 3.1e-3 | |
| Lipids and lipid-like molecules | 13 | 2.4 | 5.38× | not tested | |
| Organic nitrogen compounds | 1 | 0.7 | 1.45× | not tested | |
| Organic oxygen compounds | 6 | 4.3 | 1.39× | not tested | |
| Benzenoids | 2 | 1.6 | 1.26× | not tested | |
| Homogeneous non-metal compounds | 3 | 4.7 | 0.64× | not tested | |
| Organoheterocyclic compounds | 2 | 3.3 | 0.60× | not tested | |
| Organic acids and derivatives | 2 | 3.4 | 0.60× | not tested |
Unit: a protein (UniProt accession) with a ligand-binding domain in this X-group, counted once per superclass. Expected counts use each superclass's frequency across all ligand-binding X-groups; significance is Fisher's exact test with Benjamini–Hochberg correction. Buffers and crystallization additives are excluded. ECOD v295.2; the method follows the ECOD 2027 update, whose published figures used a slightly different artifact filter.
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB03796 | PLM | Palmitic Acid | 11 |
| DB01421 | PAR | Paromomycin | 6 |
| DB02080 | TRT | 1-{2-[2-(2-Methoxyethoxy)Ethoxy]Ethoxy}-4-(1,1,3,3-Tetramethylbutyl)Benzene | 3 |
| DB00684 | TOY | Tobramycin | 2 |
| DB03047 | EPH | L-Alpha-Phosphatidyl-Beta-Oleoyl-Gamma-Palmitoyl-Phosphatidylethanolamine | 2 |
| DB00450 | USS | Droperidol | 1 |
| DB00502 | GMJ | Haloperidol | 1 |
| DB00608 | CLQ | Chloroquine | 1 |
| DB00878 | XC9 | Chlorhexidine | 1 |
| DB01131 | XEW | Proguanil | 1 |
| DB02736 | ACM | Acetamide | 1 |
| DB03192 | — | (R)-3-hydroxydecanoyl-CoA | 1 |
| DB05636 | YMZ | (+)-Mefloquine | 1 |
| DB06894 | 1DO | 1-Dodecanol | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| CL | CHLORIDE ION | 16 |
| NAmetal | SODIUM ION | 14 |
| PLM | PALMITIC ACID | 11 |
| CAmetal | CALCIUM ION | 8 |
| PAR | PAROMOMYCIN | 6 |
| MGmetal | MAGNESIUM ION | 5 |
| P4K | polyethylene glycol | 5 |
| ZTP | (2Z,6Z,10Z,14Z,18Z,22Z,26Z)-3,7,11,15,19,23,27,31-octamethyldotriaconta-2,6,10,14,18,22,26,30-octaen-1-yl trihydrogen diphosphate | 4 |
| CUmetal | COPPER (II) ION | 3 |
| OXN | OXTOXYNOL-10 | 3 |
| TRT | FRAGMENT OF TRITON X-100 | 3 |
| E8Q | 2-azanylethyl-[(2~{S})-2,3-di(hexadecanoyloxy)propoxy]phosphinic acid | 2 |
| EPH | L-ALPHA-PHOSPHATIDYL-BETA-OLEOYL-GAMMA-PALMITOYL-PHOSPHATIDYLETHANOLAMINE | 2 |
| LMR | (2S)-2-hydroxybutanedioic acid | 2 |
| MVI | Mycinamicin VI | 2 |
| TBmetal | TERBIUM(III) ION | 2 |
| TOY | TOBRAMYCIN | 2 |
| 0K3 | (2Z,6Z,10Z,14Z,18Z,22Z,26Z)-3,7,11,15,19,23,27,31-octamethyldotriaconta-2,6,10,14,18,22,26,30-octaen-1-yl dihydrogen phosphate | 1 |
| 5LQ | 5-(3-chlorophenyl)-4-methyl-~{N}-(3-morpholin-4-ylpropyl)-1,1-bis(oxidanylidene)-1,2-thiazol-3-amine | 1 |
| 5LR | 5-(4-chlorophenyl)-~{N}-[3-(3,4-dihydro-1~{H}-isoquinolin-2-yl)propyl]-4-methyl-1,1-bis(oxidanylidene)-1,2-thiazol-3-amine | 1 |